Trial Profile
The Study of Immunogenicity of Quadrivalent Vaccine Against Human Papilloma Virus (HPV) Types 6, 11, 16, and 18 (HPV-6/11/16/18) in CKD Patients
Status:
Recruiting
Phase of Trial:
Phase IV
Latest Information Update: 27 Feb 2017
Price :
$35
*
At a glance
- Drugs Human papillomavirus vaccine recombinant quadrivalent Merck (Primary)
- Indications Cervical cancer; Human papillomavirus infections; Penile cancer
- Focus Pharmacodynamics
- 01 Feb 2011 New trial record